Rainier Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Rainier Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-218,290	Closed	-$18M	–	173
2016 Q1	$18M	Buy	218,290 +19,380	+10%	+$1.58M	0.81%	36
2015 Q4	$20.8M	Buy	198,910 +70,370	+55%	+$7.35M	0.81%	37
2015 Q3	$13.5M	Buy	+128,540	New	+$17.2M	0.5%	87
2014 Q2	–	Sell	-536,210	Closed	-$36.6M	–	193
2014 Q1	$36.6M	Sell	536,210 -391,860	-42%	-$28.9M	0.44%	79
2013 Q4	$65.2M	Sell	928,070 -326,190	-26%	-$22.2M	0.68%	55
2013 Q3	$90.6M	Sell	1,254,260 -140,310	-10%	-$9.32M	0.88%	34
2013 Q2	$77.8M	Buy	+1,394,570	New	+$86.9M	0.7%	48

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Rainier Investment Management's BMRN Position: Q2 2016 in Review

Rainier Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2016, closing a stake of 218,290 shares — an estimated $18M sold.

Rainier Investment Management first reported a position in BMRN in Q2 2013 and held it in 7 quarters. The position peaked at $90.6M in Q3 2013. 392 funds tracked by Wall St. Rank hold BMRN as of Q2 2016.

Rainier Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Rainier Investment Management sold 218,290 BioMarin Pharmaceuticals shares in Q2 2016, an estimated $18M.
Rainier Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Rainier Investment Management's BioMarin Pharmaceuticals position peaked at $90.6M in Q3 2013.
392 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2016.

Based on Rainier Investment Management's 13F filing for Q2 2016, filed 15 Aug 2016.